NCT03439488 - A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

October 10, 2019

Study Completion Date

October 10, 2019

Conditions

Chronic Hepatitis B

Interventions

DRUG

JNJ-440

JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.

DRUG

Placebo

Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.

Trial Locations (7)

Auckland Clinical Services, Auckland

Srinagarind Hospital Department of Gastroenterology, Faculty of Medicine, Khon Kaen University, Khon Kaen

Republican Clinical Hospital, Chisnau

Seoul National University Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Research Unit of Hepatitis and Liver Cancer, Department.Biochemistry, Faculty of Medicine King Chulalongkorn Memorial Hospital, Bangkok

"Limited Liability Company ARENSIA EXPLORATORY MEDICINE", Kapitanavka